Form 4: Serina Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director J Milton Harris acquired 40,000 stock options in Serina Therapeutics on April 1, 2024.
Summary
- On April 1, 2024, J Milton Harris, a director of Serina Therapeutics, acquired 40,000 stock options.
- The exercise price of these options is $11.828.
- The options vest in three equal installments on April 1, 2025, April 1, 2026, and April 1, 2027, contingent upon continued service to the issuer.
- Following this transaction, Harris directly owns 110,332 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option acquisition by a company director, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, aligning management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction: J Milton Harris acquired stock options |
| 04/01/2025 | First vesting date for stock options |
| 04/01/2026 | Second vesting date for stock options |
| 04/01/2027 | Third vesting date for stock options |
| 04/01/2034 | Expiration date for stock options |
| 04/03/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.